Skip to main content
SpringerLink
Log in

Platelet-vessel wall interactions: Implication of 5-hydroxytryptamine. A review

  • Platelets and Thrombosis
  • Published:
Agents and Actions Aims and scope Submit manuscript

Abstract

The evidence for an impact of platelet-derived 5-hydroxytryptamine (5-HT) on local tissue perfusion is reviewed. By interacting with 5-HT2 serotonergic receptors, 5-HT, directly or through amplification, activates platelets, endothelial and vascular smooth muscle cells producing platelet aggregation, vascular permeability increase and large vessel constriction. Pharmacodissection in experimental animals with selective serotonergic 5-HT2 receptor antagonists, e.g. ketanserin, shows that 5-HT largely contributes to the platelet-mediated increase in vascular permeability, to platelet-vessel wall interaction during hemostasis, to cardiopulmonary dysfunction provoked by thromboembolism and to the platelet-mediated inhibition of peripheral collateral circulation. Clinical results obtained with ketanserin further substantiate an involvement of platelet-derived 5-HT in the pathogenesis of impaired tissue perfusion in some cardiovascular conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. M. Malofiejew,The biological and pharmacological properties of some fibrinogen degradation products, Scand. J. Haematol. suppl. 13, 303–308 (1971).

    Google Scholar 

  2. J.M. Sullivan,Prostaglandins and regulation of blood pressure: clinical implications, Pharmac. There.15, 447–465 (1981).

    Article  Google Scholar 

  3. R. Verhaeghe andW. Janssens, Blood coagulation factors causing changes in vascular resistance. InVasodilation (E.P.M. Vanhoutte, andI. Leusen), pp. 141–149. Raven Press, New York 1981.

    Google Scholar 

  4. S.E. Dahlen, J. Björk, P. Hedqvist, K.E. Aarfors, S. Hammerström, J.A. Lindgren andB. Samuelsson,Leukotrienes promote plasma leakage and leukocyte adhesion in the postcapillary venules: in vivo effects with relevance to the acute inflammatory response, Proc. natn. Acad. Sci. USA78, 3887–3891 (1981).

    Google Scholar 

  5. F. De Clerck andJ.L. David,Pharmacological control of platelet and red blood cell function in the microcirculation, J. cardiovasc. Pharmac.3, 1388–1412 (1981).

    Google Scholar 

  6. F. De Clerck andJ.M. Van Nueten,Plateletmediated vascular contractions: inhibition of the serotonergic component by ketanserin, Thromb. Res.27, 713–727 (1982).

    Article  PubMed  Google Scholar 

  7. F. De Clerck andJ.M. Van Nueten,Plateletmediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker, Biochem. Pharmac.32, 765–771 (1983).

    Article  Google Scholar 

  8. H. Schmid-Schönbein, G.V.R. Born, P.P. Richardson, N. Cusack, H. Rieger, R. Forst, I. Rohling-Winbel, P. Blasberg andA. Wehmeyer,Rheology of thrombotic processes in flow: the interaction of erythrocytes and thrombocytes subjected to high flow firces, Biorheology18, 415–444 (1981).

    PubMed  Google Scholar 

  9. S.R. Coughlin, M.A. Moskowitz, H.N. Antoniades andL. Levine,Serotonin receptormediated stimulation of bovine smooth muscle cell prostacyclin synthesis and its modulation by plateletderived growth factor, Proc. natn. Acad. Sci. USA78, 7134–7138 (1981).

    Google Scholar 

  10. W. Hope, T.J. Martin, C.N. Chesterman andF.J. Morgan,Human β-thromboglubulin inhibits PGI 2 production and binds to a specific site in bovine aortic endothelial cells, Nature282, 210–212 (1979).

    PubMed  Google Scholar 

  11. A.L. Bloom andD.P. Thomas,Haemostasis and Thrombosis., pp. 593–795. Churchill Livingstone, Edinburgh 1981.

    Google Scholar 

  12. J.L. David andF. De Clerck, Detection of platelet activationin vivo: significance and limitations of the available tests. In —Hydroxytryptamine in Peripheral Reactions (Ed.F. De Clerck, andP.M. Vanhoutte), pp. 61–70. Raven Press, New York 1982.

    Google Scholar 

  13. B. Samuelsson, R. Paoletti andP.W. Ramwell,Cardiovascular system, Adv. Prostaglandin, Thromb. Leukotrienes11, 359–498 (1983).

    Google Scholar 

  14. F. De Clerck andA.G. Herman,5-Hydroxytryptamine and platelet aggregation, Fedn. Proc.42, 228–232 (1983).

    Google Scholar 

  15. M.G. Lampugnani, G. De Gaetano andE.C. Rossi,Functional distinction between serotonin uptake and serotonin-induced shape change receptors in rat platelets, Biochim. biophys. Acta693, 22–26 (1982).

    PubMed  Google Scholar 

  16. J.R. Peters andD.G. Grahame-Smith,Human platelet 5-HT-receptors: characterization and functional association, Eur. J. Pharmac.68, 243–256 (1980).

    Article  Google Scholar 

  17. F. De Clerck, J.L. David andP.A.J. Janssen,Inhibition of 5-hydroxytryptamine-induced and —amplified human platelet aggregation by ketanserin (R 4 468), a selective 5-HT 2 receptor antagonist, Agents and Actions12, 388–397 (1982).

    Google Scholar 

  18. F. De Clerck, B. Xhonneux, J. Leysen andP.A.J. Janssen,The involvement of 5-HT 2-receptor sites in the activation of cat platelets, Thromb. Res.33, 305–321 (1984).

    Article  PubMed  Google Scholar 

  19. J.E. Leysen, F. Awouters, L. Kennis, P.M. Laduron, J. Vandenberk andP.A.J. Janssen,Receptor binding profile of R 41 468, a novel antagonist a 5-HT 2 receptors, Life Sci.28, 1015–1022 (1981).

    Article  PubMed  Google Scholar 

  20. F. De Clerck, B. Xhonneux, J.E. Leysen, andP.A.J. Janssen,Evidence for the functional 5-HT 2 receptor sites on human blood platelets, Biochem. Pharmac.33, 2807–2811 (1984).

    Article  Google Scholar 

  21. D. Ee Chaffoy De Courcelles, F. De Clerck, J.E. Leysen, H. Van Belle andP.A.J. Janssen,Evidence that phospholipid turnover is the signal transducing system coupled to serotonin S 2-receptor sites, Nature (submitted) (1984).

  22. P. Erne, F.R. Bühler, H. Affolter andE. Bürgisser,Excitatory and inhibitory modulation of intracellular free calcium in human platelets by hormones and drugs, Eur. J. Pharmac.91, 331–332 (1983).

    Article  Google Scholar 

  23. J. Leempoels, W. DeCock, J. De Cree andH. Verhaegen,The effect of ketanserin on 5-HT-induced irreversible platelet aggregation in patients with cardiovascular disease, First Eur. Meeding on Hypertension, May 29–June 1, Milan (abstract) (1983).

  24. J. Bevan andS. Heptinstall,Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. Thromb. Res. 30, 415–423 (1983).

    Article  PubMed  Google Scholar 

  25. S. Haas, L.W. Schrod andG. Blümel,The antithrombotic effect of a new 5-HT 2-receptor antagonist (R41468) on experimental thrombosis in rats, Thromb. Haemostas.50, 378 (abstract) (1983).

    Google Scholar 

  26. W.R. Humphrey andJ.W. Aiken,Antithrombotic and hypotensive effects of the serotonin 2 receptor antagonist ketanserin in anaesthetized dogs, Pharmacologist24, 196 (abstract) (1982).

    Google Scholar 

  27. S.I. Said,Metabolic functions of the pulmonary circulation, Circulation Res.50, 325–333 (1982).

    PubMed  Google Scholar 

  28. F. De Clerck, M. De Brabander, H. Neels andV. Vandevelde,Direct evidence for the contractile capacity of endothelial cells, Thromb. Res.23, 505–520 (1981).

    Article  PubMed  Google Scholar 

  29. D. Shepro andP. D'Amore, Endothelial cell metabolism. InVascular Endothelium and Basement Membranes (Ed.B.M. Altura), pp. 161–201. S. Karger, Basel 1980.

    Google Scholar 

  30. G. Majno andG.E. Palade,Studies on inflammation. I. The effect of histamine and serotonin on vascular permeability: an electron microscopic study, J. biophys. biochem. Cytol.11, 571–605 (1961).

    PubMed  Google Scholar 

  31. G. Majno, G.E. Palade andG.I. Schoefl,Studies on inflammation. II. The site of action of histamine and serotonin along the vascular tree: a topographic study, J. biophys. biochem. Cytol.11, 607–626 (1961).

    PubMed  Google Scholar 

  32. G. Majno, S.M. Shea andM. Leventhal,Endothelial contractions induced by histamine-type mediators, J. Cell Biol.42, 647–672 (1969).

    Article  PubMed  Google Scholar 

  33. F. De Clerck andR.S. Reneman,Serotonin and microvascular permeability, Int. J. Microcirc. clin. Exp.-abstract (in press) (1984).

  34. G. Gabbiani, M.C. Badonnel andG. Majno,Intra-arterial injections of histamine, serotonin, or bradykinin: a topographic study of vascular leakage, Proc. Soc. exp. Biol. Med.135, 447–452 (1970).

    PubMed  Google Scholar 

  35. A.M. Northover andB.J. Northover,The effects of histamine, 5-hydroxytryptamine and bradykinin on rat mesenteric blood vessels, J. Pathol.98, 265–276 (1969).

    Article  PubMed  Google Scholar 

  36. S.P. Olesen andS. Crone,Serotonin increases microvascular permeability in the brain, Int. J. microcirc. clin. Exp.-abstract (in press) (1984).

  37. K. Udaka, Y. Tacheuchi andH.Z. Mouht,Simple methods for quantification of enhanced vascular permeability, Proc. Soc. exp. Biol. Med.133, 1384–1387 (1970).

    PubMed  Google Scholar 

  38. J.L. Beets andW. Paul,Actions of locally administered adrenoreceptor agonists on increased plasma protein extravasation and blood flow in guinea-pig skin, Br. J. Pharmac.70, 461–467 (1980).

    Google Scholar 

  39. L.A. Chahl,Interactions of bradykinin, prostaglandin E 1, 5-hydroxytryptamine, histamine and adenosine-5′-triphosphate on dye leakage response in rat skin, J. Pharm. Pharmac.28, 753–757 (1976).

    Google Scholar 

  40. M.A. Packham, E.E. Nishizawa andJ.F. Mustard,Response of platelets to tissue injury, Biochem. Pharmac.17 (Suppl.), 171–184 (1968).

    Article  Google Scholar 

  41. R.S. Reneman,The anterior and the lateral compartmental syndrome of the leg due to intensive use of muscles, Clin. Orthop.113, 69–80 (1975).

    PubMed  Google Scholar 

  42. R.S. Reneman, D.W. Slaaf, L. Lindbom, G.J. Tangelder andK.E. Arfors,Muscle blood flow disturbances produced by simultaneously elevated venous and total tissue pressure, Microvasc. Res.20, 307–318 (1980).

    Article  PubMed  Google Scholar 

  43. R.S. Reneman andA.H.M. Jageneau,The influence of weighted exercise on tissue (intramuscular) pressure in normal subjects and patients with intermittent claudication, J. clin. lab. Invest.31 (suppl. 128) 37–42 (1973).

    Google Scholar 

  44. R.A. Cohen, J.T. Shepherd andP.M. Vanhoutte:5-Hydroxytryptamine can mediate endothelium-dependent relaxation of coronary arteries, Am. J. Physiol.245, 71077–71080 (1983).

    Google Scholar 

  45. P.M. Vanhoutte andR.A. Cohen,The elusory role of serotonin in vascular function and disease, Biochem. Pharmac.32, 3671–3674 (1983).

    Article  Google Scholar 

  46. J.M. Van Nueten,5-Hydroxytryptamine and precapillary vessels, Fedn. Proc.42, 223–227 (1983).

    Google Scholar 

  47. J.M. Van Nueten andP.M. Vanhoutte,Serotonin and vascular function, Clin. Anaesth. (in press) (1984).

  48. P.M. Vanhoutte, Heterogeneity in vascular smooth muscle. InMicroocirculation (Ed.G. Kaley andB.M. Altura), pp. 181–309. University Pail Press 1978.

  49. A.P. Somlyo andA.V. Somlyo,Vascular smooth muscle. II. Pharmacology of normal and hypertensive vessels, Pharmac. Rev.22, 249–353 (1970).

    Google Scholar 

  50. J.M. Van Nueten, P.A.J. Janssen, J. Van Beek, R. Xhonneux, T.J. Verbeuren andP.M. Vanhoutte,Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT 2 serotonergic receptors, J. Pharmac. exp. Ther.218, 217–230 (1981).

    Google Scholar 

  51. R.M. Brazenor andJ.A. Angus,Actions of serotonin antogonists on dog coronary artery, Eur. J. Pharmac.81, 569–576 (1982).

    Article  Google Scholar 

  52. J.E. Leysen, C.J.E. Niemegeers, J.M. Van Nueten andP.M. Laduron, [3 H] Ketanserin (R 41 468), a selective [3 H] ligand for serotonin 2 receptor binding sites, Molec. Pharmac.21, 301–314 (1982).

    Google Scholar 

  53. M.L. Cohen, N. Mason, K.S. Wiley andR.W. Fuller,Further evidence that vascular serotonin receptors are of the 5-HT 2 type, Biochem. Pharmac.32, 567–570 (1983).

    Article  Google Scholar 

  54. J.M. Van Nueten andP.M. Vanhoutte,Effect of the Ca 2+ antagonist lidoflazine on normoxic and anoxic contractions of canine coronary arterial smooth muscle, Eur. J. Pharmac.64, 173–176 (1980).

    Article  Google Scholar 

  55. J.M. Van Nueten andP.M. Vanhoutte,Selectivity of calcium-antagonism and serotonin-antagonism with respect to venous and arterial tissues, Angiology32, 476–494 (1981).

    PubMed  Google Scholar 

  56. B.M. Altura andB.W. Zweifach,Pharmacologic properties of antihistamines in relation to vascular reactivity, Am. J. Physiol.209, 550–556 (1965).

    PubMed  Google Scholar 

  57. C. Orlandi, J.L. Blackshear andN.K. Hollenberg,Serotonin-induced arterial spasm: implications for tissue perfusion, Int. J. microcirc. clin. Exp.-abstract (in press) (1984).

  58. S.B. Acharya andD.E. McIntyre,Platelet products and vascular PGI 2 production, Prostaglandins Leukotrienes Med.10, 73–81 (1983).

    Article  Google Scholar 

  59. S.R. Coughlin, M.A. Moskowitz andL. Levine,Identification of a serotonin type 2 receptor linked to prostacyclin synthesis in vascular smooth muscle cells, Biochem. Pharmac.33, 692–695 (1984).

    Article  Google Scholar 

  60. J.M. Van Nueten, P.A.J. Janssen, W. De Ridder andP.M. Vanhoutte,Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in isolated femoral artery of the rabbit; effect of ketanserin (R 41 468), Eur. J. Pharmac.77, 281–287 (1982).

    Article  Google Scholar 

  61. J.M. Van Nueten, J.E. Leysen, F. De Clerck andP.M. Vanhoutte,Serotonergic receptor subtypes and vascular reactivity, J. cardiovasc. Pharmac., in press (1984).

  62. M. Da Prada, J.G. Richards andR. Kettler, Amine storage organelles in platelets. InPlatelets in Biology and Pathology, vol. 2 (Ed.J.L. Gordon), pp. 107–146. Elsevier-North Holland Biomedical Press, Amsterdam 1981.

    Google Scholar 

  63. E.F. Ellis, O. Oelz, L. Jacson Roberts II, N.A. Payne, B.J. Sweetman, A.S. Niess andJ.A. Oates,Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A 2, Science193, 1135–1137 (1976).

    PubMed  Google Scholar 

  64. S. Moncada andJ.R. Vane,Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A 2,and prostacyclin, Pharmac. Rev.30, 293–331 (1979).

    Google Scholar 

  65. M.I. Siegel, R.T. McConnel andP. Cuatrecasas,Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10-14,-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway, Proc. natn. Acad. Sci. USA76, 3744–3778 (1979).

    Google Scholar 

  66. S. Moncada andJ.R. Vane,Arachidonic acid metabolites and the interaction between platelets and blood vessel wall, New Engl. J. Med.300, 1142–1147 (1979).

    PubMed  Google Scholar 

  67. R.L. Nachman, B. Weksler andB. Verris,Increased vascular permeability produced by human platelet granule cationic extract, J. clin. Invest.49, 274–281 (1970).

    PubMed  Google Scholar 

  68. R.L. Nachman, B. Weksler andB. Ferris,Characterization of human platelet vascular permeability-enhancing activity, J. clin. Invest.51, 549–556 (1972).

    PubMed  Google Scholar 

  69. J.F. Mustard, H.Z. Movat, D.R.L. Macmorine andA. Senyi,Release of permeability factor from the blood platelet, Proc. Soc. exp. Biol. Med.119, 988–991 (1965).

    PubMed  Google Scholar 

  70. H. Holmsen,Prostaglandin endoperoxide — Thromboxane synthesis and dense granule secretion as positive feedback loops in the propagation of platelet responses during ‘the basic platelet reaction’, Thromb. Haemost.38, 1030–1041 (1977).

    PubMed  Google Scholar 

  71. G. Hornstra andH.C. Hemker,Clot-promoting effects of platelet-vessel wall interactions: influence of dietary fats in relation to arterial thrombus formation in rats, Haemostasis8, 211–226 (1979).

    PubMed  Google Scholar 

  72. H. Hornstra, E. Haddeman andJ.A. Don Blood platelets do not provide endoperoxides for vascular prostaglandin production, Nature279, 66–68 (1979).

    PubMed  Google Scholar 

  73. T. Ashford,Platelet aggregation of sites of minimal endothelial injury, Am. J. Pathol.53, 599–607 (1968).

    PubMed  Google Scholar 

  74. M.B. Stemerman, H. Baumgartner andT.H. Spaet,The subendothelial microfibril and platelet adhesion, Lab. Invest.24, 179–187 (1971).

    PubMed  Google Scholar 

  75. R. Forst, H. Rieger andH. Schmid-Schönbein, Stimulation of human platelets under the influence of high shear stresses in tube flow. InBasic Aspects of Blood Trauma (Ed.H. Schmid-Schöbein andP. Teitel), pp. 46–62. Martinus Nijhoff Publishers, The Hague 1979.

    Google Scholar 

  76. B.L. Thiele, I.V. Young, P.M. Chikos, J.H. Hirsch andD.E. Strandness,Correlation of arteriographic findings with symptoms in patients with cerebrovascular disease, Neurology30, 1041–1046 (1980).

    PubMed  Google Scholar 

  77. K.L. Kaplan andJ. Owen,Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo, Blood57, 199–202 (1981).

    PubMed  Google Scholar 

  78. J.R. O'Brien, M.D. Etherington, R.D. Shuttleworth andW.H. Calwell,Platelet function in acute myocardial infarction patients compared with controls, Thromb. Haemost.44, 96–99 (1981).

    Google Scholar 

  79. M.D. Rubenstein, R.T. Wall, D.S. Baim andD.C. Harrisen,Platelet activation in clinical coronary artery disease and spasm, Am. Heart J.102, 363–367 (1981).

    Article  PubMed  Google Scholar 

  80. J. Zahavi andV.V. Kakkar,β-thromboglobulin — a Specific marker of in vivo platelet release reaction. Thromb. Haemost.44, 23–29 (1980).

    PubMed  Google Scholar 

  81. M.D. McGoon andP.M. Vanhoutte,Serotonin is the predominant mediator of platelet-evoked contraction of canine pulmonary artery, Circulation68, 400 (1983).

    PubMed  Google Scholar 

  82. R.F.W. Moulds, V. Iwanov andR.L. Medcalf,The sensitivity of human vascular smooth muscle to platelet-derived vasoactive agents, Aust. Soc. clin. exp. Pharmac., Dec. 14–16, Adelaïde, (abstract) (1981).

  83. P.W. Braunstein, H.F. Cuenoud, I. Joris andG. Majno,Platelets, fibroblasts, and inflammation, Am. J. Pathol.99, 53–66 (1980).

    PubMed  Google Scholar 

  84. G.S. Basran, A. Dewar, J. Morley, C.P. Page, W. Paul andL. Wood,Properties of platelet activating factor (PAF-acether) which suggest involvement in chronic inflamation and persistent asthma, Br. J. Pharmac.77, 437P (1982).

  85. F. De Clerck, Y. Somers andL. Van Gorp,Evidence for a contribution of platelet-derived 5-hydroxytryptamine to hemostasis in the rat, Agents and Action (in press) (1984).

  86. W.V. Huval, M.A. Mathieson, L.I. Stemp, B.M. Dunham, A.G. Jones, D. Shepro andH.B. Hechtman,Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism, Ann. Surg.197, 220–25 (1983).

    PubMed  Google Scholar 

  87. M.M. Todd, J.B. Forrest andD.B.J. Cragg,The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism, Am. Heart J.105, 769–776 (1983).

    Article  PubMed  Google Scholar 

  88. A. Nevelsteen, F. De Clerck, W. Loots andA. De Grijse,Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT 2-receptor antagonist, Archs. int. Pharmacodyn. Ther.270, 268–279, 1984.

    Google Scholar 

  89. R.G. Schaub, K.M. Meyers andR. Sande,Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis, J. lab. Clin. Med.90, 645–653 (1977).

    PubMed  Google Scholar 

  90. R.G. Schaub, K.M. Meyers, R. Sande andG. Hamilton,Inhibition of feline collateral vessel development following thrombotic occlusion, Circulation Res.39, 736–743 (1976).

    PubMed  Google Scholar 

  91. A. Verheyen, E. Vlaminckx, F. Lauwers, C. Van Den Broeck andL. Wouters,Serotonin-induced blood flow changes in the rat hindlegs after unilateral ligation of the femoral artery. Inhibition by the S 2 receptor antagonist ketanserin, Archs. int. Pharmacodyn. Ther.270, 280–298 (1984).

    Google Scholar 

  92. F. Dreyfuss andJ. Zahavi,Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemia heart disease, Atherosclerosis17, 107–120 (1973).

    Article  PubMed  Google Scholar 

  93. H.C. Kwaan, J. A. Colwell, S. Cruz, N. Suwanela andJ.G. Dobbie,Increased platelet aggregation in diabetes mellitus, J. Lab. clin. Med.80, 236–246 (1972).

    PubMed  Google Scholar 

  94. O. Al-Mefty, G. Marano, S. Rajaraman, G.R. Nugent andN. Rodman,Transient ischemic attacks due to increased platelet aggregation and adhesiveness. Ultrastructural and functional correlation, J. Neurosurg.50, 449–453 (1979).

    PubMed  Google Scholar 

  95. M. Matsumo, M. Kusunoki, O. Uyama, A. Fujisawa, T. Matsuyama, S. Yoneda, K. Kimura andH. Abe,Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or cerebrovascular disease, Prostaglandins Med.7, 553–562 (1981).

    Article  PubMed  Google Scholar 

  96. J.H. Joist, R. Kendall Baker andG. Schnofield,Increased in vivo and in vitro platelet function in type II- and type IV-hyperlipoproteinaemia, Thromb. Res.15, 95–108 (1979).

    Article  PubMed  Google Scholar 

  97. J. Zahavi, W.A.P. Hamilton, J.J.G. O'Reilly, J. Leyton, L.T. Cotton andV.V. Kakkar,Plasma exchange and platelet function in Raynaud's phenomenon, Thromb. Res.19, 85–93 (1983).

    Article  Google Scholar 

  98. S. Cocheri andP. Fiorentini,Platelet adhesiveness and aggregation in hypertensive patients, Acta med. scand.525, 273–275 (1971).

    Google Scholar 

  99. A. Poplawski, M. Skorulska, andS. Micwiarowski,Increased platelet adhesiveness in hypertensive cardiovascular disease, J. Atheroscler. Res.8, 721–723 (1968).

    PubMed  Google Scholar 

  100. N.D. Vlachakis andL. Aldedort,Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines, and platelet aggregation, Am. J. Cardiol.45, 321–324 (1980).

    Article  PubMed  Google Scholar 

  101. C. Ludlam, A. Bolton, S. Moore andJ. Cash,New Rapid method for diagnosis of deep venous thrombosis, LancetII, 259–260 (1975).

    Article  Google Scholar 

  102. M. Denham, M. Fischer, G. James andM. Hassan,Beta thromboglobulin and heparin neutralizing activity test in clinical conditions, LancetI, 1154 (1977).

    Google Scholar 

  103. Baele, H. Bogaerts, D. L. Clement, R. Pannier andF. Barbier,Platelet activation during treatmill excercise in patients with chronic peripheral arterial disease, Thromb. Res.23, 215–223 (1981).

    Article  PubMed  Google Scholar 

  104. S.E. Kjeldsen, K. Gjesdal, I. Eide, I. Aakesson, R. Amundsen, O.P. Foss andP. Leren,Increased beta-thromboglobulin in essential hypertension; interactions between arterial plasma adrenaline, platelet function and blood lipids, Acta med. scand.213, 359–373 (1983).

    Google Scholar 

  105. J. Mehta andP. Mehta,Platelet function in hypertension and effect of therapy, Am. J. Cardiol.47, 331–334 (1981).

    Article  PubMed  Google Scholar 

  106. B. Boneu, A. Fournie, P. Sci, H. Grandjean, R. Bierme andG. Pontonnier,Platelet production time, uricemia and some hemostasis tests in preeclampsia, Eur. J. Obstet. Gynecol. Reprod. Biol.11, 85–94 (1980).

    Article  PubMed  Google Scholar 

  107. J.I. De Vries, E. Vellenga andJ.G. Aarnoudse,Plasma beta-thromboglobulin in normal preganancy and pregnancy-induced hypertension, Eur. J. Obstet. Gynecol. Reprod. Biol.19, 209–216 (1983).

    Article  Google Scholar 

  108. C. Redman, M. Allington, F. Bolton andG. Stirrat,Plasma thromboglobulin in pre-eclampsia, LancetII, 248 (1977).

    Article  Google Scholar 

  109. F.E. Preston, J.D. Ward, B.H. Marcola, N.R. Porter andW.R. Timperley,Elevated β-thromboglobulin levels and circulating platelet aggregates in diabetic microangiopathy, LancetI, 238–240 (1978).

    Article  Google Scholar 

  110. A. Burrows, S. Chavin andT. Hockaday,Plasma thromboglobulin concentrations in diabetes mellitus, LancetI, 235–237 (1978).

    Article  Google Scholar 

  111. R.I. Leny, L. Wiener, P. Walinsky, A.M. Lefer, M.J. Silver andJ.B. Smith,Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature, Circulation61, 1165–1171 (1980).

    PubMed  Google Scholar 

  112. J. Mehta, P. Mehta, R.L. Feldman andC. Horalek,Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina, Am. Heart J.107, 286–292 (1984).

    Article  PubMed  Google Scholar 

  113. J. Mehta, P. Mehta, R. Zipper andC. Horalek,Thromboxane/prostacyclin equilibrium at rest and during exercise in man. Its relationship to myocardial ischemia, Clin. Res.29, 223A, (abstract) (1981).

    Google Scholar 

  114. R.M. Robertson, D. Robertson, L.J. Roberts, R.L. Maas, G.A. Fitzgerald, G.C. Friesinger andJ.A. Oates,Thromboxane A 2 in vasotonic angina pectoris, New Engl. J. Med.304, 998–1003 (1981).

    PubMed  Google Scholar 

  115. M. Tada, T. Kiziua andM. Inove,Elevation of thromboxane B 2 levels in patients with classic and variant angina pectoris, Circulation64, 1107–1115 (1981).

    PubMed  Google Scholar 

  116. K.P. Bhargava, N. Rhina, N. Misra, K. Shanker andS. Vrat,Uptake of serotonin by human platelets and its relevance to CNS involvement in hypertension, Life Sci.25, 195–199 (1979).

    Article  PubMed  Google Scholar 

  117. K.E. Whigham, P.W. Howie, A.M. Drummond andC.R.M. Prentile,Abnormal platelet function in pre-eclampsia, Br. J. obstet. Gynecol.85, 28–32 (1978).

    Google Scholar 

  118. R.D. Shuttleworth andJ.R. O'Brien,Intraplatelet serotonin and plasma hydroxyindoles in health and disease, Blood57, 505–509 (1981).

    PubMed  Google Scholar 

  119. A.H.M. Jageneau, Ch. Hörig, W. Loots andJ. Symoens,Plethysmographic registration of volume changes in a hand vein. Effects of serotonin and a specific antagonist, Angiology31, 828–832 (1982).

    Google Scholar 

  120. A. Halpern, P.H. Kuhn, H.E. Shaftel, S.S. Samuels, N. Shaftel, D. Selman andH.G. Birch,Raynaud's disease, Raynaud's phenomenon, and serotonin, Angiology11, 151–167 (1960).

    PubMed  Google Scholar 

  121. G.C. Scroop andJ.A. Walsh,Interactions between angiotensin, noradrenaline and serotonin on the peripheral blood vessels in man, Aust. J. exp. Biol. med. Sci.46, 573–580 (1978).

    Google Scholar 

  122. D. Hechtman andA. Jageneau,Inhibition of cold-induced vasoconstriction with ketanserin, Ann. Surg. (in press) [1984].

  123. M.J.H.M. Jacobs, D.W. Slaaf, R.J. Reneman andH.A.J. Lemmens,Haemorheological and microcirculatory measurements in patients with Raynaud's phenomenon, before and after treatment with ketanserin, (Submitted for publication) (1984).

  124. J.R. Siebold andA.H.M. Jageneau,Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin 2 (5-HT 2)receptor, Arthritis Rheum.27, 139–146 (1984).

    PubMed  Google Scholar 

  125. E. Stranden, O. K. Roald andK. Krogh,Treatment of Raynaud's phenomenon with the 5-HT 2-receptor antagonist ketanserin, Br. med. J.285, 1069–1071 (1982).

    Google Scholar 

  126. M.E. Burrows andP.M. Vanhoutte,Pharmacology of arterioles: some aspects of variability in response to norepinephrine, histamine and 5-hydroxytryptamine, J. cardiovasc. Pharmac.3, 1370–1380 (1981).

    Google Scholar 

  127. S.J. Peroutka andS. H. Snyder,Multiple serotonin receptors: differential binding of [3 H] 5-hydroxytrytamine, [3 H] lysergic acid diethylamine and [3 H] spiroperidol, Molec. Pharmac.16, 687–694 (1974).

    Google Scholar 

  128. J.M. Van Nueten, W. De Ridder andJ. Van Beek,Hypoxia and spasms in the cerebral vasculature, J. Cerebr. Blood Flow and Metabolism2, S29–31 (1982).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Life Sciences, Laboratory of Haematology, B-2340, Beerse, Belgium

    F. De Clerck

  2. Department of Pharmacology, Janssen Pharmaceutica Research Laboratories, B-2340, Beerse, Belgium

    J. M. van Nueten

  3. Department of Physiology, University of Limburg, Maastricht, The Netherlands

    R. S. Reneman

Authors
  1. F. De Clerck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. van Nueten
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. S. Reneman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Clerck, F., van Nueten, J.M. & Reneman, R.S. Platelet-vessel wall interactions: Implication of 5-hydroxytryptamine. A review. Agents and Actions 15, 612–626 (1984). https://doi.org/10.1007/BF01966783

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01966783

Keywords

Search

Navigation